AVI BioPharma inks agreement with researchers at Karolinska Institutet
Under the agreement, both the parties are expected to investigate RNA-based drug candidates using AVI’s proprietary, intrinsically charge-neutral, phosphorodiamidate morpholino oligomer (PMO) based chemistry platform. The intellectual property
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.